false
0001904286
0001904286
2026-11-16
2026-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 16, 2026
MIRA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
| Florida |
|
001-41765 |
|
85-3354547 |
| (State
or Other Jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
Incorporation) |
|
File
Number) |
|
Identification
No.) |
1200
Brickell Avenue, Suite 1950 #1183
Miami,
Florida
(Address
of Principal Executive Offices)
Registrant’s
telephone number, including area code: (786) 432-9792
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common
Stock, $0.0001 par value per share |
|
MIRA |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01 Regulation FD Disclosure.
MIRA-55:
New Receptor Selectivity Findings Support a Potentially Differentiated Non-Opioid Approach to Pain
On
November 16, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) is furnishing information regarding new pharmacological findings
for MIRA-55, its investigational oral drug candidate for inflammatory pain. Expanded receptor screening demonstrated substantial separation
between MIRA-55’s potent CB2 receptor activation and measured interactions with other biological targets, including more than 500-fold
separation from mu, delta, and kappa opioid receptor interactions, respectively. MIRA-55 also showed no substantial inhibition of COX-1
or COX-2 at the tested concentrations. These findings support a potentially differentiated, non-opioid approach to treating inflammatory
pain through biological pathways distinct from those targeted by conventional opioid and COX-inhibiting medications.
The
new findings build on previously reported studies demonstrating potent CB2 activation, measurable CB1 activity, brain penetration following
oral administration in animals, and distinct effects on β-arrestin and Gi/cAMP signaling. CB2 helps regulate pain, inflammation,
and the body’s response to tissue injury, while CB1 influences how pain signals are transmitted and processed by the nervous system.
MIRA-55’s brain penetration may provide an opportunity to influence central pain-processing pathways in addition to peripheral
inflammation. Its pathway-dependent pharmacology, characterized by inhibition of agonist-induced β-arrestin recruitment with limited
antagonism of Gi/cAMP signaling, may also provide a potential basis for a differentiated CNS behavioral profile.
Supporting
this pharmacological profile, previously reported animal studies demonstrated encouraging analgesic and anti-inflammatory effects, including
greater pain relief than injected morphine in an acute inflammatory pain model and sustained pain relief comparable to celecoxib in a
separate chronic inflammatory pain study, under the conditions tested. Additional behavioral studies demonstrated an anxiolytic-like
signal and encouraging exploratory behaviors, alongside the absence of significant THC-like motor impairment. Together, these findings
support continued development of MIRA-55 as a potentially differentiated treatment for inflammatory pain. The Company is advancing MIRA-55
through preclinical and IND-enabling activities, targeting an Investigational New Drug (IND) submission in the first half of 2027.
The
Company intends to distribute a press release regarding these findings on November 17, 2026. A copy of the press release is furnished
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The
information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such filing.
Cautionary
Note Regarding Forward-Looking Statements
This
report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,”
“plan,” “can,” “could,” “would,” “may,” “will,” “believe,”
“estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,”
“intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements
include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential,
mechanism of action, development plans, regulatory pathway, safety profile, efficacy, anticipated clinical development, commercialization
prospects, market opportunity, and future development of MIRA-55, SKNY-1, Ketamir-2, and the Company’s other product candidates.
These
forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s current
beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical
and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual
property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors”
contained in the Company’s Annual Report on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange
Commission (“SEC”).
Forward-looking
statements contained in this report speak only as of the date of this report, and the Company undertakes no obligation to update or revise
these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable
law.
Investors
are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding these and other risks
and uncertainties is contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K and subsequent filings,
available at www.sec.gov and in the Investors section of the Company’s website at www.mirapharmaceuticals.com. Forward-looking
statements should be considered in light of these risks and uncertainties.
Item
9.01 Financial Statements and Other Exhibits.
(d)
Exhibits.
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press Release of MIRA Pharmaceuticals, Inc., dated November 17, 2026 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
MIRA
PHARMACEUTICALS, INC. |
| |
|
| Dated:
November 16, 2026 |
By: |
/s/
Erez Aminov |
| |
Name: |
Erez
Aminov |
| |
Title: |
Chief
Executive Officer |
Exhibit
99.1
MIRA
Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain
New
Findings Highlight MIRA-55’s Potent CB2 Activation With More Than 500-Fold Separation From Measured Mu, Delta, and Kappa Opioid
Receptor Interactions
MIRA-55’s
Differentiated Profile Combines CB2/CB1 Activity, Brain Penetration, and Distinct Signaling With Encouraging Preclinical Pain Relief,
Reduced Inflammation, and Anxiolytic-Like Effects Without Significant THC-Like Motor Impairment
MIAMI,
Nov. 17, 2026 (GLOBE NEWSWIRE) — MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”),
a clinical-stage pharmaceutical company developing novel oral therapies for neurologic, inflammatory and metabolic disorders, today announced
new pharmacological findings for MIRA-55, its investigational oral drug candidate for inflammatory pain.
Expanded
receptor screening demonstrated substantial separation between MIRA-55’s potent CB2 receptor activation and measured interactions
with other biological targets, including approximately 680-fold separation from mu opioid receptors and 540-fold separation from kappa
opioid receptors. The compound also showed no substantial inhibition of COX-1 or COX-2 at the tested concentrations, suggesting a selective
pharmacological approach distinct from conventional opioid and COX-inhibiting pain or anti-inflammatory medications.
These
findings build on MIRA-55’s previously reported pharmacological and preclinical results, providing additional support for its development
as a potentially differentiated non-opioid treatment for inflammatory pain.
A
Potentially Differentiated Mechanism for Inflammatory Pain
MIRA-55’s
potential differentiation extends beyond activation of a single receptor. Previously reported studies demonstrated potent CB2 activation
alongside measurable CB1 activity, two receptors involved in complementary biological pathways associated with pain and inflammation.
CB2
helps regulate inflammation, pain sensitivity, and the body’s response to tissue injury, while CB1 plays an important role in how
pain signals are transmitted and processed by the nervous system. Together, these activities raise the possibility that MIRA-55 could
address both the underlying inflammatory processes contributing to pain and the neurological pathways involved in pain perception.
Previously
reported studies also demonstrated that orally administered MIRA-55 reaches brain tissue in animals. This is particularly relevant because
pain is not only generated at the site of inflammation but is also processed and regulated by the brain. Brain penetration may therefore
provide MIRA-55 with the opportunity to influence central pain-processing pathways in addition to peripheral inflammation.
MIRA-55
has also demonstrated distinct effects on β-arrestin and Gi/cAMP signaling, two pathways through which cannabinoid receptors regulate
cellular activity. Functional studies showed inhibition of agonist-induced β-arrestin recruitment with limited antagonism of Gi/cAMP
signaling. This distinction may be particularly important because broad disruption of CB1 signaling has been associated with psychiatric
adverse effects in previously developed cannabinoid-targeting drugs. MIRA-55’s pathway-dependent pharmacology may provide a potential
basis for a differentiated CNS behavioral profile. Supporting this possibility, previously reported animal studies demonstrated an anxiolytic-like
signal and encouraging exploratory behaviors, alongside the absence of significant THC-like motor impairment.
Previously
reported animal studies also demonstrated encouraging analgesic and anti-inflammatory effects. In an acute inflammatory pain model, oral
MIRA-55 demonstrated greater pain relief than injected morphine, while a separate chronic inflammatory pain study showed sustained pain
relief comparable to celecoxib, alongside reductions in inflammation-associated swelling.
Scientific
Perspective
“What
makes MIRA-55 particularly compelling is the possibility of addressing pain through complementary biological pathways,” said Dr.
Itzchak Angel, CSA of MIRA. “Our findings suggest a pharmacological profile that may influence both the inflammatory processes
that contribute to pain and how pain signals are processed in the nervous system. The combination of brain penetration, distinct receptor
signaling, a broad receptor selectivity profile, and encouraging preclinical efficacy without significant THC-like motor impairment gives
us a strong scientific rationale for believing MIRA-55 could represent a differentiated approach to pain treatment.”
Management
Commentary
“We’re
building a differentiated pain franchise focused on significant unmet medical needs,” said Erez Aminov, CEO of MIRA. “MIRA-55
is designed to address inflammatory pain, while Ketamir-2 targets neuropathic pain and is advancing toward Phase 2 proof of concept in
chemotherapy-induced peripheral neuropathy. Our strategy is to translate encouraging science into clinical evidence that can support
meaningful treatment options for patients and create long-term value through future strategic partnerships.”
Development
Outlook
MIRA
continues advancing MIRA-55 through preclinical and IND-enabling activities, targeting an Investigational New Drug (IND) submission in
the first half of 2027.
Additional
preclinical evaluations are ongoing, including measurements of inflammatory cytokines to further characterize MIRA-55’s effects
on inflammatory signaling.
About
MIRA Pharmaceuticals, Inc.
MIRA
Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company developing novel oral therapies designed to address significant
unmet medical needs in pain and metabolic disorders. The Company is building a differentiated pain therapeutics franchise alongside an
oral obesity program. Its lead candidate, Ketamir-2, is being developed for neuropathic pain, initially targeting chemotherapy-induced
peripheral neuropathy (CIPN). Ketamir-2 has successfully completed Phase 1 clinical testing and is advancing toward Phase 2a under an
active IND. MIRA’s pipeline also includes MIRA-55, an investigational oral therapy for inflammatory pain, and SKNY-1, an investigational
oral therapy for obesity. Following scientific review, the U.S. Drug Enforcement Administration has determined that all three candidates
are not classified as controlled substances.
About
MIRA-55
MIRA-55
is an investigational novel oral synthetic cannabinoid analog being developed for inflammatory pain. The compound has demonstrated potent
CB2 activation, measurable CB1 activity, brain penetration, and distinct receptor signaling across β-arrestin and Gi/cAMP pathways.
Preclinical studies have also shown encouraging analgesic and anti-inflammatory activity, anxiolytic-like effects, and exploratory behavioral
findings without significant THC-like motor impairment.
Cautionary
Note Regarding Forward-Looking Statements
This
press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,”
“plan,” “can,” “could,” “would,” “may,” “will,” “believe,”
“estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,”
“intend,” “seek,” “target,” and other words of similar meaning, although not all forward-looking
statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic
potential, mechanism of action, development plans, regulatory pathway, safety profile, efficacy, anticipated clinical development, commercialization
prospects, market opportunity, and future development of MIRA-55, SKNY-1, Ketamir-2, and the Company’s other product candidates.
These
forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s current
beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical
and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual
property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors”
contained in the Company’s Annual Report on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange
Commission (“SEC”).
Forward-looking
statements contained in this press release speak only as of the date of this press release, and the Company undertakes no obligation
to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as
required by applicable law.
Investors
are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding these and other risks
and uncertainties is contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K and subsequent filings,
available at www.sec.gov and in the Investors section of the Company’s website at www.mirapharmaceuticals.com. Forward-looking
statements should be considered in light of these risks and uncertainties.
Investor
and Media Contact
Krystina
Quintana
MIRA
Pharmaceuticals
info@mirapharma.com
(786)
432-9792